Molbio Diagnostics Raises ₹281.5 Cr from Anchor Investors for IPO

Molbio Diagnostics recently secured ₹281.5 crore from anchor investors, gearing up for its upcoming Initial Public Offering. The point-of-care diagnostics company allocated 34.87 lakh equity shares to 33 investors.

Anchor Investor Breakdown

• Amount Raised: ₹281.5 crore
• Shares Allocated: 34.87 lakh equity shares
• Anchor Investors: 33
• Price Per Share: ₹807 (upper limit of price band)

A significant portion of this allocation went to domestic Mutual Funds and Life Insurance companies. This highlights broad institutional interest in the Goa-based firm.

Institutional Interest

• Domestic Mutual Funds: 23.54 lakh equity shares (67.51%) across 9 funds via 19 schemes
• Life Insurance Companies: 2.65 lakh equity shares (7.62%) to 10 companies

Prominent investors like Temasek and Motilal Oswal Private Equity support Molbio. The anchor book attracted several major global and domestic players.

Key Participants

• Global Funds: Goldman Sachs, BlackRock Global Funds, International Finance Corporation
• Indian Funds: HDFC MF, Mirae Asset, Nippon India Mutual Fund, ICICI Pru AMC, Kotak Mahindra AMC, Tata MF, Edelweiss MF, WhiteOak Capital
• Insurers: HDFC Life Insurance, Bajaj Life Insurance

The IPO for Molbio Diagnostics is scheduled for August 2026. The company aims to raise a substantial amount at its upper price band.

Upcoming IPO Details

• Subscription Period: Monday, August 10, 2026 to Wednesday, August 12, 2026
• Price Band: ₹768 to ₹807 per equity share
• Target Raise: ₹940 crore at the upper end of the price band